Smith & Nephew plc (SNN)
| Market Cap | 12.45B -12.8% |
| Revenue (ttm) | 6.30B +6.0% |
| Net Income | 635.00M +29.3% |
| EPS | 1.46 +31.8% |
| Shares Out | 851.12M |
| PE Ratio | 20.47 |
| Forward PE | 13.81 |
| Dividend | $0.76 (2.56%) |
| Ex-Dividend Date | Oct 2, 2026 |
| Volume | 1,155,542 |
| Open | 30.02 |
| Previous Close | 30.32 |
| Day's Range | 29.79 - 30.11 |
| 52-Week Range | 26.12 - 37.09 |
| Beta | 0.67 |
| Analysts | Hold |
| Price Target | 33.19 (+11.26%) |
| Earnings Date | Aug 4, 2026 |
About SNN
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for SNN stock is "Hold." The 12-month stock price target is $33.19, which is an increase of 11.26% from the latest price.
News
Smith & Nephew price target raised to 1,040 GBp from 1,020 GBp at Barclays
Barclays raised the firmās price target on Smith & Nephew to 1,040 GBp from 1,020 GBp and keeps an Underweight rating on the shares.
Smith & Nephew Breaks Below 200-Day Moving Average - Notable for SNN
In trading on Tuesday, shares of Smith & Nephew plc (Symbol: SNN) crossed below their 200 day moving average of $30.95, changing hands as low as $30.39 per share. Smith & Nephew plc shares are current...
Smith & Nephew SNATS Q3 Earnings Call Highlights
Smith & Nephew SNATS NYSE: SNN lowered its full-year revenue and trading profit outlook after continued weakness in its U.S. knee and hip businesses tempered otherwise stronger third-quarter growth.
Smith & Nephew price target raised to $33 from $30 at Canaccord
Canaccord raised the firmās price target on Smith & Nephew to $33 from $30 and keeps a Hold rating on the shares. The firm said they delivered another challenged quarterā¦
Smith & Nephew Earnings Call Transcript: Q3 2026
Q3 underlying growth accelerated to 3.4%, led by Sports Medicine and ENT, while U.S. Orthopedics remained weak. FY26 revenue growth guidance was reduced to ~3%, with trading profit of ~$1.25bn and free cash flow of ~$750m expected.
Smith & Nephew Slides: Q3 2026
Smith & Nephew has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Smith & Nephew Earnings release: Q3 2026
Smith & Nephew released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Smith & Nephew plc Reports Q3 2026 Revenue of $1,551 million and Revises Full-Year Guidance
Smith & Nephew plc reported its third quarter 2026 trading update, with revenue of $1,551 million compared to $1,501 million in the third quarter of 2025, representing 3.4% revenue growth on both an u...
Smith & Nephew Q3 Revenues Rise, Cuts FY26 Outlook; Continues To Explore Options For Orthopaedics
(RTTNews) - Smith & Nephew Plc (SNN, SN.L), a British medical technology company, reported Wednesday higher revenues in its third quarter, with growth in all regions. Further, the company trimmed fisc...
Smith+Nephew cuts outlook after failed orthopaedics deal talks with J&J
Smith+Nephew cut its full-year revenue and profit forecast on Wednesday as the British medical device maker also confirmed āthat talks about a potential merger with Johnson & Johnson's (JNJ.N), opens ...
Smith & Nephew price target lowered to 1,380 GBp from 1,550 GBp at Citi
Citi analyst Veronika Dubajova lowered the firmās price target on Smith & Nephew to 1,380 GBp from 1,550 GBp and keeps a Buy rating on the shares. Published first onā¦
Smith & Nephew merger talks with J&J orthopaedics unit collapse over CEO role, FT reports
Smith & Nephew's talks with Johnson & Johnson to combine with the US groupās orthopaedics division fell apart after the London-listed group refused to agree to its former CEO leading the merged busine...
Smith & Nephew plc Announces Sterling Dividend Amount of 11.65 Pence per Share
Smith & Nephew plc announced that UK shareholders and those who have validly elected to receive sterling dividends will receive an interim dividend of 11.65 pence per share. As announced on 4 August 2...
Smith & Nephew announces commercial availability of Cartiheal Agili-C in Europe
Smith & Nephew announced that its Cartiheal Agili-C Cartilage Repair Implant is now commercially available in Europe. The Cartiheal Implant will be at this weekās International Cartilage Regeneration ...
Smith+Nephew lanza en Europa el innovador implante de reparación de cartĆlago CARTIHEAL⢠AGILI-Cā¢, que serĆ” protagonista en el Congreso ICRS de Portugal
Smith+Nephew (LSE: SN, NYSE: SNN), compaƱĆa global de tecnologĆa mĆ©dica, anuncia hoy que su innovador implante de reparación de cartĆlago CARTIHEAL AGILI-C ya estĆ” disponible para su comercialización ...
Smith+Nephew lancia in Europa CARTIHEAL⢠AGILI-Cā¢, l'innovativo impianto per la riparazione della cartilagine, che sarĆ presentato all'ICRS Summit in Portogallo.
Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l'innovativo impianto per la riparazione della cartilagine. La tecnologia...
Smith+Nephew's revolutionary CARTIHEAL⢠AGILI-C⢠Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The CART...
Smith & Nephew removed from European Conviction List at Goldman Sachs
Goldman Sachs analysts removed Smith & Nephew from the firmās European Conviction List as part of its monthly update.
MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS⢠PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, to...
Smith+Nephew launches the new EVOS⢠PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, to...
Smith & Nephew receives 510k clearance from FDA, completes cases with LANDMARK
Smith+Nephew announces it received 510(k) clearance from the U.S. Food and Drug Administration, FDA, and has completed the first surgical cases with LANDMARK Total Knee System. āIt is truly aā¦
Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Cong...
Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds
Smith+Nephew announces results of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, GB / ACCESS Newswire / September 16, 2026 / Smith+Nephew, the global med...
Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds
Smith+Nephew announces pricing of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, UK / ACCESS Newswire / September 15, 2026 / Smith+Nephew, the global med...
Smith & Nephew price target raised to $33.88 from $33.77 at Berenberg
Berenberg raised the firmās price target on Smith & Nephew to $33.88 from $33.77 and keeps a Hold rating on the shares.